Blog Archive

Αλέξανδρος Γ. Σφακιανάκης

Monday, July 26, 2021

Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure

xlomafota13 shared this article with you from Inoreader

SocialThumb.00008390.DC.jpeg

Combined immunotherapy is associated with a significant risk of severe and potentially fatal immune-related adverse events (irAEs). Therefore, we retrospectively analyzed the side profile and efficacy of low-dose ipilimumab (1 mg/kg, IPI1) combined with anti-PD-1 immunotherapy in patients who progressed after anti-PD-1 mo notherapy. Nine patients with unresectable stage III or IV melanoma treated with combined low-dose ipilimumab (1 mg/kg, IPI1) and anti-PD-1 immunotherapy, following progression after anti-PD-1 treatment, were identified. Treatment response and irAEs were recorded. Grade 3 irAEs occurred in one-third of patients. Interestingly, there were no grade 4 or 5 irAEs. In fact, four out of the nine patients experienced no irAEs at all. One patient discontinued combined immunotherapy due to immune-related colitis. The mean time to the onset of grade 3 irAEs was 14.3 weeks. The objective response rate was 33.3% and a disease control rate of 66.7% was achieved. Median progression-free survival (PFS) was 5.7 months and median overall survival (OS) was 21.6 months. The median PFS when IPI1 and anti-PD-1 treatment was administered in the second-line setting was not reached, but only 2.8 months when used in subsequent treatment settings. Combined IPI1 and anti-PD-1 immunotherapy was well to lerated. Its use in the third-line or above setting was associated with a significantly poorer prognosis than in the second-line setting. Larger, prospective studies are required to evaluate the safety and efficacy of this dosing regimen following anti-PD-1 treatment failure. * Dr. Ewan A. Langan and Dr. Patrick Terheyden contributed equally to the writing of this article. Received 10 May 2021 Accepted 21 May 2021 Correspondence to Patrick Terheyden, MB, ChB, PhD, Department of Dermatology, University Clinic, Schleswig Holstein, Ratzeburger Allee, Luebeck, 23560, Germany Tel: +49 451 500 41510; e-mail: patrick.terheyden@uksh.de Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
View on the web

No comments:

Post a Comment